 | • レポートコード：D005-00614 • 出版社/出版日：GlobalInfoResearch / 2020年5月29日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール • 産業分類：医療・製薬 |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥783,000 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、悪性中皮腫薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。悪性中皮腫薬の種類別市場規模（ペメトレキセド、シスプラチン、カルボプラチン、ゲムシタビン、ビノレルビン、その他）、用途別市場規模（病院薬局、小売薬局、腫瘍センター、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：AstraZeneca、Eli Lilly、Merck、Bristol-Myers Squibb、Sanofi、Roche、Boehringer Ingelheim GmbH、Pfizer、Novartis、Teva Pharmaceuticals、Concordia International、MolMed、Mylan、Nichi-Iko Pharmaceutical、Kyowa Hakko Kirin、Corden Pharma、Fresenius Kabi、Ono Pharmaceutical、Polaris Pharmaceuticals、Sun Pharmaceuticals ・地域別グローバル市場分析 2015年-2020年 ・悪性中皮腫薬の北米市場（アメリカ、カナダ、メキシコ） ・悪性中皮腫薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・悪性中皮腫薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・悪性中皮腫薬の南米市場（ブラジル、アルゼンチン） ・悪性中皮腫薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：ペメトレキセド、シスプラチン、カルボプラチン、ゲムシタビン、ビノレルビン、その他 ・用途別分析：病院薬局、小売薬局、腫瘍センター、その他 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The global Malignant Mesothelioma Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Malignant Mesothelioma Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Malignant Mesothelioma Drugs market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Malignant Mesothelioma Drugs market has been segmented into:
Pemetrexed
Cisplatin
Carboplatin
Gemcitabine
Vinorelbine
Other
By Application, Malignant Mesothelioma Drugs has been segmented into:
Hospital Pharmacies
Retail Pharmacies
Oncology Centers
Other
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Malignant Mesothelioma Drugs market presented in the report. This section sheds light on the sales growth of different regional and country-level Malignant Mesothelioma Drugs markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Malignant Mesothelioma Drugs market.
The report offers in-depth assessment of the growth and other aspects of the Malignant Mesothelioma Drugs market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Malignant Mesothelioma Drugs Market Share Analysis
Malignant Mesothelioma Drugs competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Malignant Mesothelioma Drugs sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Malignant Mesothelioma Drugs sales, revenue and market share for each player covered in this report.
The major players covered in Malignant Mesothelioma Drugs are:
AstraZeneca
Eli Lilly
Merck
Bristol-Myers Squibb
Sanofi
Roche
Boehringer Ingelheim GmbH
Pfizer
Novartis
Teva Pharmaceuticals
Concordia International
MolMed
Mylan
Nichi-Iko Pharmaceutical
Kyowa Hakko Kirin
Corden Pharma
Fresenius Kabi
Ono Pharmaceutical
Polaris Pharmaceuticals
Sun Pharmaceuticals
Table of Contents
1 Malignant Mesothelioma Drugs Market Overview
1.1 Product Overview and Scope of Malignant Mesothelioma Drugs
1.2 Classification of Malignant Mesothelioma Drugs by Type
1.2.1 Global Malignant Mesothelioma Drugs Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Malignant Mesothelioma Drugs Revenue Market Share by Type in 2019
1.2.3 Pemetrexed
1.2.4 Cisplatin
1.2.5 Carboplatin
1.2.6 Gemcitabine
1.2.7 Vinorelbine
1.2.8 Other
1.3 Global Malignant Mesothelioma Drugs Market by Application
1.3.1 Overview: Global Malignant Mesothelioma Drugs Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Oncology Centers
1.3.5 Other
1.4 Global Malignant Mesothelioma Drugs Market by Regions
1.4.1 Global Malignant Mesothelioma Drugs Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Malignant Mesothelioma Drugs (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Malignant Mesothelioma Drugs Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Malignant Mesothelioma Drugs Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Malignant Mesothelioma Drugs Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Malignant Mesothelioma Drugs Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Malignant Mesothelioma Drugs Status and Prospect (2015-2025)
2 Company Profiles
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 AstraZeneca SWOT Analysis
2.1.4 AstraZeneca Product and Services
2.1.5 AstraZeneca Malignant Mesothelioma Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.2 Eli Lilly
2.2.1 Eli Lilly Details
2.2.2 Eli Lilly Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Eli Lilly SWOT Analysis
2.2.4 Eli Lilly Product and Services
2.2.5 Eli Lilly Malignant Mesothelioma Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.3 Merck
2.3.1 Merck Details
2.3.2 Merck Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Merck SWOT Analysis
2.3.4 Merck Product and Services
2.3.5 Merck Malignant Mesothelioma Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.4 Bristol-Myers Squibb
2.4.1 Bristol-Myers Squibb Details
2.4.2 Bristol-Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Bristol-Myers Squibb SWOT Analysis
2.4.4 Bristol-Myers Squibb Product and Services
2.4.5 Bristol-Myers Squibb Malignant Mesothelioma Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.5 Sanofi
2.5.1 Sanofi Details
2.5.2 Sanofi Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Sanofi SWOT Analysis
2.5.4 Sanofi Product and Services
2.5.5 Sanofi Malignant Mesothelioma Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.6 Roche
2.6.1 Roche Details
2.6.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Roche SWOT Analysis
2.6.4 Roche Product and Services
2.6.5 Roche Malignant Mesothelioma Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.7 Boehringer Ingelheim GmbH
2.7.1 Boehringer Ingelheim GmbH Details
2.7.2 Boehringer Ingelheim GmbH Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Boehringer Ingelheim GmbH SWOT Analysis
2.7.4 Boehringer Ingelheim GmbH Product and Services
2.7.5 Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.8 Pfizer
2.8.1 Pfizer Details
2.8.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Pfizer SWOT Analysis
2.8.4 Pfizer Product and Services
2.8.5 Pfizer Malignant Mesothelioma Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.9 Novartis
2.9.1 Novartis Details
2.9.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Novartis SWOT Analysis
2.9.4 Novartis Product and Services
2.9.5 Novartis Malignant Mesothelioma Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.10 Teva Pharmaceuticals
2.10.1 Teva Pharmaceuticals Details
2.10.2 Teva Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Teva Pharmaceuticals SWOT Analysis
2.10.4 Teva Pharmaceuticals Product and Services
2.10.5 Teva Pharmaceuticals Malignant Mesothelioma Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.11 Concordia International
2.11.1 Concordia International Details
2.11.2 Concordia International Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Concordia International SWOT Analysis
2.11.4 Concordia International Product and Services
2.11.5 Concordia International Malignant Mesothelioma Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.12 MolMed
2.12.1 MolMed Details
2.12.2 MolMed Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 MolMed SWOT Analysis
2.12.4 MolMed Product and Services
2.12.5 MolMed Malignant Mesothelioma Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.13 Mylan
2.13.1 Mylan Details
2.13.2 Mylan Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 Mylan SWOT Analysis
2.13.4 Mylan Product and Services
2.13.5 Mylan Malignant Mesothelioma Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.14 Nichi-Iko Pharmaceutical
2.14.1 Nichi-Iko Pharmaceutical Details
2.14.2 Nichi-Iko Pharmaceutical Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 Nichi-Iko Pharmaceutical SWOT Analysis
2.14.4 Nichi-Iko Pharmaceutical Product and Services
2.14.5 Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.15 Kyowa Hakko Kirin
2.15.1 Kyowa Hakko Kirin Details
2.15.2 Kyowa Hakko Kirin Major Business and Total Revenue (Financial Highlights) Analysis
2.15.3 Kyowa Hakko Kirin SWOT Analysis
2.15.4 Kyowa Hakko Kirin Product and Services
2.15.5 Kyowa Hakko Kirin Malignant Mesothelioma Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.16 Corden Pharma
2.16.1 Corden Pharma Details
2.16.2 Corden Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.16.3 Corden Pharma SWOT Analysis
2.16.4 Corden Pharma Product and Services
2.16.5 Corden Pharma Malignant Mesothelioma Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.17 Fresenius Kabi
2.17.1 Fresenius Kabi Details
2.17.2 Fresenius Kabi Major Business and Total Revenue (Financial Highlights) Analysis
2.17.3 Fresenius Kabi SWOT Analysis
2.17.4 Fresenius Kabi Product and Services
2.17.5 Fresenius Kabi Malignant Mesothelioma Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.18 Ono Pharmaceutical
2.18.1 Ono Pharmaceutical Details
2.18.2 Ono Pharmaceutical Major Business and Total Revenue (Financial Highlights) Analysis
2.18.3 Ono Pharmaceutical SWOT Analysis
2.18.4 Ono Pharmaceutical Product and Services
2.18.3 Ono Pharmaceutical Malignant Mesothelioma Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.19 Polaris Pharmaceuticals
2.19.1 Polaris Pharmaceuticals Details
2.19.2 Polaris Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.19.3 Polaris Pharmaceuticals SWOT Analysis
2.19.4 Polaris Pharmaceuticals Product and Services
2.19.5 Polaris Pharmaceuticals Malignant Mesothelioma Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.20 Sun Pharmaceuticals
2.20.1 Sun Pharmaceuticals Details
2.20.2 Sun Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.20.3 Sun Pharmaceuticals SWOT Analysis
2.20.4 Sun Pharmaceuticals Product and Services
2.20.5 Sun Pharmaceuticals Malignant Mesothelioma Drugs Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Malignant Mesothelioma Drugs Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Malignant Mesothelioma Drugs Players Market Share
3.2.2 Top 10 Malignant Mesothelioma Drugs Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Malignant Mesothelioma Drugs Revenue and Market Share by Regions
4.2 North America Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
4.3 Europe Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
4.5 South America Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
5 North America Malignant Mesothelioma Drugs Revenue by Countries
5.1 North America Malignant Mesothelioma Drugs Revenue by Countries (2015-2020)
5.2 USA Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
5.3 Canada Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
5.4 Mexico Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
6 Europe Malignant Mesothelioma Drugs Revenue by Countries
6.1 Europe Malignant Mesothelioma Drugs Revenue by Countries (2015-2020)
6.2 Germany Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
6.3 UK Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
6.4 France Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
6.5 Russia Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
6.6 Italy Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Malignant Mesothelioma Drugs Revenue by Countries
7.1 Asia-Pacific Malignant Mesothelioma Drugs Revenue by Countries (2015-2020)
7.2 China Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
7.3 Japan Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
7.4 Korea Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
7.5 India Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
8 South America Malignant Mesothelioma Drugs Revenue by Countries
8.1 South America Malignant Mesothelioma Drugs Revenue by Countries (2015-2020)
8.2 Brazil Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
8.3 Argentina Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Malignant Mesothelioma Drugs by Countries
9.1 Middle East & Africa Malignant Mesothelioma Drugs Revenue by Countries (2015-2020)
9.2 Saudi Arabia Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
9.3 UAE Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
9.4 Egypt Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
9.5 South Africa Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Malignant Mesothelioma Drugs Revenue and Market Share by Type (2015-2020)
10.2 Global Malignant Mesothelioma Drugs Market Forecast by Type (2019-2024)
10.3 Pemetrexed Revenue Growth Rate (2015-2025)
10.4 Cisplatin Revenue Growth Rate (2015-2025)
10.5 Carboplatin Revenue Growth Rate (2015-2025)
10.6 Gemcitabine Revenue Growth Rate (2015-2025)
10.7 Vinorelbine Revenue Growth Rate (2015-2025)
10.8 Other Revenue Growth Rate (2015-2025)
11 Global Malignant Mesothelioma Drugs Market Segment by Application
11.1 Global Malignant Mesothelioma Drugs Revenue Market Share by Application (2015-2020)
11.2 Malignant Mesothelioma Drugs Market Forecast by Application (2019-2024)
11.3 Hospital Pharmacies Revenue Growth (2015-2020)
11.4 Retail Pharmacies Revenue Growth (2015-2020)
11.5 Oncology Centers Revenue Growth (2015-2020)
11.6 Other Revenue Growth (2015-2020)
12 Global Malignant Mesothelioma Drugs Market Size Forecast (2021-2025)
12.1 Global Malignant Mesothelioma Drugs Market Size Forecast (2021-2025)
12.2 Global Malignant Mesothelioma Drugs Market Forecast by Regions (2021-2025)
12.3 North America Malignant Mesothelioma Drugs Revenue Market Forecast (2021-2025)
12.4 Europe Malignant Mesothelioma Drugs Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Malignant Mesothelioma Drugs Revenue Market Forecast (2021-2025)
12.6 South America Malignant Mesothelioma Drugs Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Malignant Mesothelioma Drugs Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Malignant Mesothelioma Drugs Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Malignant Mesothelioma Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Malignant Mesothelioma Drugs Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Malignant Mesothelioma Drugs Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. AstraZeneca Corporate Information, Location and Competitors
Table 6. AstraZeneca Malignant Mesothelioma Drugs Major Business
Table 7. AstraZeneca Malignant Mesothelioma Drugs Total Revenue (USD Million) (2017-2018)
Table 8. AstraZeneca SWOT Analysis
Table 9. AstraZeneca Malignant Mesothelioma Drugs Product and Solutions
Table 10. AstraZeneca Malignant Mesothelioma Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Eli Lilly Corporate Information, Location and Competitors
Table 12. Eli Lilly Malignant Mesothelioma Drugs Major Business
Table 13. Eli Lilly Malignant Mesothelioma Drugs Total Revenue (USD Million) (2018-2019)
Table 14. Eli Lilly SWOT Analysis
Table 15. Eli Lilly Malignant Mesothelioma Drugs Product and Solutions
Table 16. Eli Lilly Malignant Mesothelioma Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Merck Corporate Information, Location and Competitors
Table 18. Merck Malignant Mesothelioma Drugs Major Business
Table 19. Merck Malignant Mesothelioma Drugs Total Revenue (USD Million) (2017-2018)
Table 20. Merck SWOT Analysis
Table 21. Merck Malignant Mesothelioma Drugs Product and Solutions
Table 22. Merck Malignant Mesothelioma Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Bristol-Myers Squibb Corporate Information, Location and Competitors
Table 24. Bristol-Myers Squibb Malignant Mesothelioma Drugs Major Business
Table 25. Bristol-Myers Squibb Malignant Mesothelioma Drugs Total Revenue (USD Million) (2017-2018)
Table 26. Bristol-Myers Squibb SWOT Analysis
Table 27. Bristol-Myers Squibb Malignant Mesothelioma Drugs Product and Solutions
Table 28. Bristol-Myers Squibb Malignant Mesothelioma Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Sanofi Corporate Information, Location and Competitors
Table 30. Sanofi Malignant Mesothelioma Drugs Major Business
Table 31. Sanofi Malignant Mesothelioma Drugs Total Revenue (USD Million) (2017-2018)
Table 32. Sanofi SWOT Analysis
Table 33. Sanofi Malignant Mesothelioma Drugs Product and Solutions
Table 34. Sanofi Malignant Mesothelioma Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Roche Corporate Information, Location and Competitors
Table 36. Roche Malignant Mesothelioma Drugs Major Business
Table 37. Roche Malignant Mesothelioma Drugs Total Revenue (USD Million) (2017-2018)
Table 38. Roche SWOT Analysis
Table 39. Roche Malignant Mesothelioma Drugs Product and Solutions
Table 40. Roche Malignant Mesothelioma Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Boehringer Ingelheim GmbH Corporate Information, Location and Competitors
Table 42. Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Major Business
Table 43. Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Total Revenue (USD Million) (2017-2018)
Table 44. Boehringer Ingelheim GmbH SWOT Analysis
Table 45. Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Product and Solutions
Table 46. Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Pfizer Corporate Information, Location and Competitors
Table 48. Pfizer Malignant Mesothelioma Drugs Major Business
Table 49. Pfizer Malignant Mesothelioma Drugs Total Revenue (USD Million) (2017-2018)
Table 50. Pfizer SWOT Analysis
Table 51. Pfizer Malignant Mesothelioma Drugs Product and Solutions
Table 52. Pfizer Malignant Mesothelioma Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Novartis Corporate Information, Location and Competitors
Table 54. Novartis Malignant Mesothelioma Drugs Major Business
Table 55. Novartis Malignant Mesothelioma Drugs Total Revenue (USD Million) (2017-2018)
Table 56. Novartis SWOT Analysis
Table 57. Novartis Malignant Mesothelioma Drugs Product and Solutions
Table 58. Novartis Malignant Mesothelioma Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Teva Pharmaceuticals Corporate Information, Location and Competitors
Table 60. Teva Pharmaceuticals Malignant Mesothelioma Drugs Major Business
Table 61. Teva Pharmaceuticals Malignant Mesothelioma Drugs Total Revenue (USD Million) (2017-2018)
Table 62. Teva Pharmaceuticals SWOT Analysis
Table 63. Teva Pharmaceuticals Malignant Mesothelioma Drugs Product and Solutions
Table 64. Teva Pharmaceuticals Malignant Mesothelioma Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Concordia International Corporate Information, Location and Competitors
Table 66. Concordia International Malignant Mesothelioma Drugs Major Business
Table 67. Concordia International Malignant Mesothelioma Drugs Total Revenue (USD Million) (2017-2018)
Table 68. Concordia International SWOT Analysis
Table 69. Concordia International Malignant Mesothelioma Drugs Product and Solutions
Table 70. Concordia International Malignant Mesothelioma Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 71. MolMed Corporate Information, Location and Competitors
Table 72. MolMed Malignant Mesothelioma Drugs Major Business
Table 73. MolMed Malignant Mesothelioma Drugs Total Revenue (USD Million) (2017-2018)
Table 74. MolMed SWOT Analysis
Table 75. MolMed Malignant Mesothelioma Drugs Product and Solutions
Table 76. MolMed Malignant Mesothelioma Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 77. Mylan Corporate Information, Location and Competitors
Table 78. Mylan Malignant Mesothelioma Drugs Major Business
Table 79. Mylan Malignant Mesothelioma Drugs Total Revenue (USD Million) (2017-2018)
Table 80. Mylan SWOT Analysis
Table 81. Mylan Malignant Mesothelioma Drugs Product and Solutions
Table 82. Mylan Malignant Mesothelioma Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 83. Nichi-Iko Pharmaceutical Corporate Information, Location and Competitors
Table 84. Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Major Business
Table 85. Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Total Revenue (USD Million) (2017-2018)
Table 86. Nichi-Iko Pharmaceutical SWOT Analysis
Table 87. Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Product and Solutions
Table 88. Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 89. Kyowa Hakko Kirin Corporate Information, Location and Competitors
Table 90. Kyowa Hakko Kirin Malignant Mesothelioma Drugs Major Business
Table 91. Kyowa Hakko Kirin Malignant Mesothelioma Drugs Total Revenue (USD Million) (2017-2018)
Table 92. Kyowa Hakko Kirin SWOT Analysis
Table 93. Kyowa Hakko Kirin Malignant Mesothelioma Drugs Product and Solutions
Table 94. Kyowa Hakko Kirin Malignant Mesothelioma Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 95. Corden Pharma Corporate Information, Location and Competitors
Table 96. Corden Pharma Malignant Mesothelioma Drugs Major Business
Table 97. Corden Pharma Malignant Mesothelioma Drugs Total Revenue (USD Million) (2017-2018)
Table 98. Corden Pharma SWOT Analysis
Table 99. Corden Pharma Malignant Mesothelioma Drugs Product and Solutions
Table 100. Corden Pharma Malignant Mesothelioma Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 101. Fresenius Kabi Corporate Information, Location and Competitors
Table 102. Fresenius Kabi Malignant Mesothelioma Drugs Major Business
Table 103. Fresenius Kabi Malignant Mesothelioma Drugs Total Revenue (USD Million) (2017-2018)
Table 104. Fresenius Kabi SWOT Analysis
Table 105. Fresenius Kabi Malignant Mesothelioma Drugs Product and Solutions
Table 106. Fresenius Kabi Malignant Mesothelioma Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 107. Ono Pharmaceutical Malignant Mesothelioma Drugs Type and Application
Table 108. Ono Pharmaceutical Malignant Mesothelioma Drugs Major Business
Table 109. Ono Pharmaceutical Malignant Mesothelioma Drugs Total Revenue (USD Million) (2017-2018)
Table 110. Ono Pharmaceutical SWOT Analysis
Table 111. Ono Pharmaceutical Malignant Mesothelioma Drugs Product and Solutions
Table 112. Ono Pharmaceutical Malignant Mesothelioma Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 113. Polaris Pharmaceuticals Corporate Information, Location and Competitors
Table 114. Polaris Pharmaceuticals Malignant Mesothelioma Drugs Major Business
Table 115. Polaris Pharmaceuticals Malignant Mesothelioma Drugs Total Revenue (USD Million) (2017-2018)
Table 116. Polaris Pharmaceuticals SWOT Analysis
Table 117. Polaris Pharmaceuticals Malignant Mesothelioma Drugs Product and Solutions
Table 118. Polaris Pharmaceuticals Malignant Mesothelioma Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 119. Sun Pharmaceuticals Corporate Information, Location and Competitors
Table 120. Sun Pharmaceuticals Malignant Mesothelioma Drugs Major Business
Table 121. Sun Pharmaceuticals Malignant Mesothelioma Drugs Total Revenue (USD Million) (2017-2018)
Table 122. Sun Pharmaceuticals SWOT Analysis
Table 123. Sun Pharmaceuticals Malignant Mesothelioma Drugs Product and Solutions
Table 124. Sun Pharmaceuticals Malignant Mesothelioma Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 125. Global Malignant Mesothelioma Drugs Revenue (Million USD) by Players (2015-2020)
Table 126. Global Malignant Mesothelioma Drugs Revenue Share by Players (2015-2020)
Table 127. Global Malignant Mesothelioma Drugs Revenue (Million USD) by Regions (2015-2020)
Table 128. Global Malignant Mesothelioma Drugs Revenue Market Share by Regions (2015-2020)
Table 129. North America Malignant Mesothelioma Drugs Revenue by Countries (2015-2020)
Table 130. North America Malignant Mesothelioma Drugs Revenue Market Share by Countries (2015-2020)
Table 131. Europe Malignant Mesothelioma Drugs Revenue (Million USD) by Countries (2015-2020)
Table 132. Asia-Pacific Malignant Mesothelioma Drugs Revenue (Million USD) by Countries (2015-2020)
Table 133. South America Malignant Mesothelioma Drugs Revenue by Countries (2015-2020)
Table 134. South America Malignant Mesothelioma Drugs Revenue Market Share by Countries (2015-2020)
Table 135. Middle East and Africa Malignant Mesothelioma Drugs Revenue (Million USD) by Countries (2015-2020)
Table 136. Middle East and Africa Malignant Mesothelioma Drugs Revenue Market Share by Countries (2015-2020)
Table 137. Global Malignant Mesothelioma Drugs Revenue (Million USD) by Type (2015-2020)
Table 138. Global Malignant Mesothelioma Drugs Revenue Share by Type (2015-2020)
Table 139. Global Malignant Mesothelioma Drugs Revenue Forecast by Type (2021-2025)
Table 140. Global Malignant Mesothelioma Drugs Revenue by Application (2015-2020)
Table 141. Global Malignant Mesothelioma Drugs Revenue Share by Application (2015-2020)
Table 142. Global Malignant Mesothelioma Drugs Revenue Forecast by Application (2021-2025)
Table 143. Global Malignant Mesothelioma Drugs Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Malignant Mesothelioma Drugs Picture
Figure 2. Global Malignant Mesothelioma Drugs Revenue Market Share by Type in 2019
Figure 3. Pemetrexed Picture
Figure 4. Cisplatin Picture
Figure 5. Carboplatin Picture
Figure 6. Gemcitabine Picture
Figure 7. Vinorelbine Picture
Figure 8. Other Picture
Figure 9. Malignant Mesothelioma Drugs Revenue Market Share by Application in 2019
Figure 10. Hospital Pharmacies Picture
Figure 11. Retail Pharmacies Picture
Figure 12. Oncology Centers Picture
Figure 13. Other Picture
Figure 14. Global Malignant Mesothelioma Drugs Revenue (USD Million) and Growth Rate (2015-2025)
Figure 15. North America Malignant Mesothelioma Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Europe Malignant Mesothelioma Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Asia-Pacific Malignant Mesothelioma Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. South America Malignant Mesothelioma Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Middle East and Africa Malignant Mesothelioma Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 20. Global Malignant Mesothelioma Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 21. Global Malignant Mesothelioma Drugs Revenue Share by Players in 2019
Figure 22. Global Top 5 Players Malignant Mesothelioma Drugs Revenue Market Share in 2019
Figure 23. Global Top 10 Players Malignant Mesothelioma Drugs Revenue Market Share in 2019
Figure 24. Key Players Market Share Trend
Figure 25. Global Malignant Mesothelioma Drugs Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 26. Global Malignant Mesothelioma Drugs Revenue Market Share by Regions (2015-2020)
Figure 27. Global Malignant Mesothelioma Drugs Revenue Market Share by Regions in 2018
Figure 28. North America Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
Figure 29. Europe Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
Figure 30. Asia-Pacific Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
Figure 31. South America Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
Figure 32. Middle East and Africa Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
Figure 33. North America Malignant Mesothelioma Drugs Revenue Market Share by Countries (2015-2020)
Figure 34. North America Malignant Mesothelioma Drugs Revenue Market Share by Countries in 2019
Figure 35. USA Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
Figure 36. Canada Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
Figure 37. Mexico Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
Figure 38. Europe Malignant Mesothelioma Drugs Revenue Market Share by Countries (2015-2020)
Figure 39. Europe Malignant Mesothelioma Drugs Revenue Market Share by Countries in 2019
Figure 40. Germany Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
Figure 41. UK Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
Figure 42. France Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
Figure 43. Russia Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
Figure 44. Italy Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
Figure 45. Asia-Pacific Malignant Mesothelioma Drugs Revenue Market Share by Countries (2015-2020)
Figure 46. Asia-Pacific Malignant Mesothelioma Drugs Revenue Market Share by Countries in 2019
Figure 47. China Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
Figure 48. Japan Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
Figure 49. Korea Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
Figure 50. India Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
Figure 51. Southeast Asia Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
Figure 52. South America Malignant Mesothelioma Drugs Revenue Market Share by Countries (2015-2020)
Figure 53. South America Malignant Mesothelioma Drugs Revenue Market Share by Countries in 2019
Figure 54. Brazil Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
Figure 55. Argentina Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
Figure 56. Middle East and Africa Malignant Mesothelioma Drugs Revenue Market Share by Countries (2015-2020)
Figure 57. Middle East and Africa Malignant Mesothelioma Drugs Revenue Market Share by Countries in 2019
Figure 58. Saudi Arabia Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
Figure 59. UAE Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
Figure 60. Egypt Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
Figure 61. South Africa Malignant Mesothelioma Drugs Revenue and Growth Rate (2015-2020)
Figure 62. Global Malignant Mesothelioma Drugs Revenue Share by Type (2015-2020)
Figure 63. Global Malignant Mesothelioma Drugs Revenue Share by Type in 2019
Figure 64. Global Malignant Mesothelioma Drugs Market Share Forecast by Type (2021-2025)
Figure 65. Global Pemetrexed Revenue Growth Rate (2015-2020)
Figure 66. Global Cisplatin Revenue Growth Rate (2015-2020)
Figure 67. Global Carboplatin Revenue Growth Rate (2015-2020)
Figure 68. Global Gemcitabine Revenue Growth Rate (2015-2020)
Figure 69. Global Vinorelbine Revenue Growth Rate (2015-2020)
Figure 70. Global Other Revenue Growth Rate (2015-2020)
Figure 71. Global Malignant Mesothelioma Drugs Revenue Share by Application (2015-2020)
Figure 72. Global Malignant Mesothelioma Drugs Revenue Share by Application in 2019
Figure 73. Global Malignant Mesothelioma Drugs Market Share Forecast by Application (2021-2025)
Figure 74. Global Hospital Pharmacies Revenue Growth Rate (2015-2020)
Figure 75. Global Retail Pharmacies Revenue Growth Rate (2015-2020)
Figure 76. Global Oncology Centers Revenue Growth Rate (2015-2020)
Figure 77. Global Other Revenue Growth Rate (2015-2020)
Figure 78. Global Malignant Mesothelioma Drugs Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 79. Global Malignant Mesothelioma Drugs Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 80. Global Malignant Mesothelioma Drugs Revenue Market Share Forecast by Regions (2021-2025)
Figure 81. North America Malignant Mesothelioma Drugs Revenue Market Forecast (2021-2025)
Figure 82. Europe Malignant Mesothelioma Drugs Revenue Market Forecast (2021-2025)
Figure 83. Asia-Pacific Malignant Mesothelioma Drugs Revenue Market Forecast (2021-2025)
Figure 84. South America Malignant Mesothelioma Drugs Revenue Market Forecast (2021-2025)
Figure 85. Middle East and Africa Malignant Mesothelioma Drugs Revenue Market Forecast (2021-2025)
Figure 86. Sales Channel: Direct Channel vs Indirect Channel
悪性中皮腫の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Malignant Mesothelioma market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 5.7% in the forecast period of 2020 to 2025 and will expected to reach USD 541.1 million by 2025, from USD 432.8 million in 2019. The Malignant Mesot…- 悪性中皮腫治療の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Malignant Mesothelioma Therapeutic market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Malignant …
- 悪性神経膠腫治療薬の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Malignant Glioma Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Malignant Glioma Drugs…
- 悪性神経膠腫の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Malignant Glioma market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Malignant Glioma market repo…
- 悪性神経膠腫治療の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Malignant Glioma Therapeutic market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Malignant Glioma…